GSK (LON:GSK) Announces Earnings Results

GSK (LON:GSK) posted its quarterly earnings data on Wednesday. The company reported GBX 172 earnings per share (EPS) for the quarter, reports. GSK had a return on equity of 18.08% and a net margin of 8.02%.

GSK Price Performance

GSK stock opened at GBX 2,180 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The company has a 50-day moving average price of GBX 1,838.36 and a 200 day moving average price of GBX 1,660.84. GSK has a 12-month low of GBX 1,242.50 and a 12-month high of GBX 2,066. The stock has a market cap of £87.96 billion, a P/E ratio of 16.39, a PEG ratio of 1.24 and a beta of 0.31.

Insider Activity at GSK

In other GSK news, insider Wendy Becker acquired 441 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was bought at an average cost of GBX 1,809 per share, for a total transaction of £7,977.69. Also, insider Jonathan Symonds bought 2,500 shares of the business’s stock in a transaction on Thursday, February 5th. The shares were acquired at an average cost of GBX 2,114 per share, with a total value of £52,850. In the last three months, insiders bought 4,591 shares of company stock valued at $9,069,269. Corporate insiders own 0.20% of the company’s stock.

Key GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: EU approves GSK’s RSV vaccine for adults — lifts near‑term commercial prospects and adds a new, durable revenue stream that supports upside to sales and margins. GSK RSV Vaccine Wins EU Adult Approval As Shares Trade Above Targets
• Positive Sentiment: Q4 2025 results beat/strong metrics — revenue up ~13.8% YoY and EPS surged; cash flow improvement and margin expansion cited in earnings headlines, which supports the rally and analyst optimism. GSK PLC (GSK) Q4 2025 Earnings Call Highlights
• Positive Sentiment: Broker support — Shore Capital reaffirmed a Buy and set a GBX 2,300 price target, adding institutional endorsement that can feed further buying interest. Digital Look
• Neutral Sentiment: Third‑party data shows large one‑off profit moves in some reports (very large YoY EPS increases that may reflect accounting items); investors should check company filings for recurring earnings quality. QuiverQuant earnings summary
• Neutral Sentiment: Analyses on valuation after a ~47% one‑year gain — some pieces question whether upside is already priced in, making future moves dependent on execution and guidance. Is GSK Still Attractive After A 47% One-Year Share Price Gain
• Negative Sentiment: Management flags slower sales growth in 2026 — the company’s first outlook under the new CEO calls for decelerated sales growth next year, which raises near‑term expectations risk and moderates the positive reaction to the quarter. GSK sees slower sales growth in 2026
• Negative Sentiment: Coverage noting profit rise but concerns of slower growth next year — echoing guidance caution and suggesting investors may take profits or demand clearer medium‑term traction. GSK sees profits rise but fears slowdown in growth next year

Analyst Upgrades and Downgrades

Several research analysts recently commented on GSK shares. UBS Group reissued a “neutral” rating and issued a GBX 1,940 price objective on shares of GSK in a research note on Friday, January 23rd. Citigroup reiterated a “buy” rating and issued a GBX 1,900 target price on shares of GSK in a research report on Tuesday, January 27th. Shore Capital restated a “buy” rating and set a GBX 2,300 price target on shares of GSK in a research report on Wednesday. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,100 price objective on shares of GSK in a research note on Wednesday, January 7th. Finally, JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, GSK has a consensus rating of “Hold” and a consensus target price of GBX 1,867.86.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.